ANI Pharmaceuticals, Inc.
ANIPHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company carries a $1.70B market cap, placing it firmly in the small-cap category. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Market Cap
$1.70B
Beta
0.46
P/E (TTM)
19.09
P/E (Fwd)
7.03
EPS (TTM)
$3.91
EPS (Fwd)
$10.61
ROE
18.3%
ROA
5.0%
Cash
$326.1M
Total Debt
$630.2M
Free CF
$140.3M
52W Change
22.6%
Annual Financials
Cash vs Debt
The company holds $326.1M in cash, though total debt stands at $630.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $140.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 18.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 5.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $316.4M (2022) to $883.4M (2025), reflecting a 179% increase over the period.
ANIP's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ANIP.